CFM
BMRN icon

Catalyst Funds Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Catalyst Funds Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-20,800
Closed -$1.24M – 597
2025
Q4 		$1.24M Buy
+20,800
New +$1.13M 0.29% 86
2024
Q4 		– Sell
-400
Closed -$28.1K – 442
2024
Q3 		$28.1K Buy
+400
New +$33.4K 0.01% 1001

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Catalyst Funds Management's BMRN Position: Q1 2026 in Review

Catalyst Funds Management sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2026, closing a stake of 20,800 shares — an estimated $1.24M sold.

Catalyst Funds Management first reported a position in BMRN in Q3 2024 and held it in 2 quarters. The position peaked at $1.24M in Q4 2025. 559 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • Catalyst Funds Management reported no remaining BioMarin Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Catalyst Funds Management sold 20,800 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $1.24M.
  • Catalyst Funds Management first reported a position in BioMarin Pharmaceuticals in Q3 2024 and held it in 2 quarters.
  • Catalyst Funds Management's BioMarin Pharmaceuticals position peaked at $1.24M in Q4 2025.
  • 559 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Catalyst Funds Management's 13F filing for Q1 2026, filed 11 May 2026.